BioSyent Inc. (TSXV:RX)

Market Cap	176.03M +40.8%
Revenue (ttm)	42.18M +22.2%
Net Income	8.63M +21.5%
EPS	0.75 +24.8%
Shares Out	11.50M
PE Ratio	20.50
Forward PE	16.03
Dividend	0.22 (1.45%)
Ex-Dividend Date	Feb 27, 2026

Volume	2,674
Average Volume	5,079
Open	14.92
Previous Close	15.20
Day's Range	14.92 - 15.31
52-Week Range	9.20 - 15.80
Beta	0.60
RSI	54.09
Earnings Date	Mar 19, 2026

About BioSyent

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: RX

Financial Performance

In 2024, BioSyent's revenue was 35.03 million, an increase of 10.89% compared to the previous year's 31.59 million. Earnings were 7.27 million, an increase of 12.54%.